Trial | NCT00703898  Report issue

Title

Durability of Nevirapine-Based Antiretroviral Regimen
Durability of Stavudine, Lamivudine and Nevirapine Among Advanced HIV-1 Infected Patients With/Without Prior Co-Administration of Rifampicin: A 144-Week Prospective Study

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    nevirapine ...

  • Study Participants

    140
Although nevirapine is used as an alternative to efavirenz for initial regimen in developed countries, nevirapine has still been a key antiretroviral drug in many resource-limited countries including Thailand due to its accessibility and affordability. In addition, a component of stavudine and lamivudine is still widely used as a backbone in the antiretroviral regimen in this setting.To date, data on the durability of a regimen of stavudine, lamivudine and nevirapine are very limited, particularly from the resource-limited settings.
Study Started
Nov 30
2004
Primary Completion
Dec 31
2009
Study Completion
Apr 30
2010
Last Update
Jul 08
2008
Estimate

Drug nevirapine

200 mg/day twice a day

  • Other names: GPO-vir

Criteria 

Inclusion Criteria:

HIV-infected individuals ≥15 years of age
CD4 cell count <350 cells/mm3
Willing to participate and give consent form

Exclusion Criteria:

previous antiretroviral therapy
pregnancy
receiving a medication that has drug-drug interactions with NVP or RFP
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >5 times of upper limit of normal range
No Results Posted